Interim estimate of influenza vaccine effectiveness in hospitalised children, Hong Kong, 2017/18 by Chiu, SSS et al.
Title Interim estimate of influenza vaccine effectiveness inhospitalised children, Hong Kong, 2017/18
Author(s) Chiu, SSS; Kwan, YW; Feng, S; Wong, JSC; Leung, CW; Chan,LY; Peiris, JSM; Cowling, BJ
Citation Eurosurveillance, 2018, v. 23 n. 8, p. pii=18-00062:1-pii=18-00062:5
Issued Date 2018
URL http://hdl.handle.net/10722/251733
Rights
Eurosurveillance. Copyright © European Centre for Disease
Prevention and Control.; This work is licensed under a Creative
Commons Attribution-NonCommercial-NoDerivatives 4.0
International License.
1www.eurosurveillance.org
Rapid communications
Interim estimate of influenza vaccine effectiveness in 
hospitalised children, Hong Kong, 2017/18
Susan S Chiu1,2, Mike Y W Kwan2,3, Shuo Feng⁴, Joshua S C Wong³, Chi-Wai Leung³, Eunice L Y Chan¹, J S Malik Peiris4,5, Benjamin J 
Cowling⁴
1. Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital and Li Ka Shing Faculty of Medicine, The University 
of Hong Kong, Hong Kong Special Administrative Region, China
2. These authors contributed equally to this article
3. Department of Paediatrics and Adolescent Medicine, Princess Margaret Hospital, Hong Kong Special Administrative Region, 
China
4. World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li 
Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China
5. Center of Influenza Research, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative 
Region, China
Correspondence: Benjamin J Cowling (bcowling@hku.hk)
Citation style for this article: 
Chiu Susan S, Kwan Mike Y W, Feng Shuo, Wong Joshua S C, Leung Chi-Wai, Chan Eunice L Y, Peiris J S Malik, Cowling Benjamin J. Interim estimate of influenza 
vaccine effectiveness in hospitalised children, Hong Kong, 2017/18. Euro Surveill. 2018;23(8):pii=18-00062. https://doi.org/10.2807/1560-7917.ES.2018.23.8.18-
00062 
Article submitted on 09 Feb 2018 / accepted on 20 Feb 2018 / published on 22 Feb 2018
We conducted a hospital-based test-negative study in 
Hong Kong to estimate influenza vaccine effectiveness 
(VE) for the winter of 2017/18. The interim analysis 
included data on 1,078 children admitted between 4 
December 2017 and 31 January 2018 with febrile acute 
respiratory illness and tested for influenza. We esti-
mated influenza VE at 66% (95% confidence interval 
(CI): 43–79) overall, and 65% (95% CI: 40–80) against 
influenza B, the dominant virus type (predominantly 
B/Yamagata).
Ongoing monitoring of influenza vaccine effectiveness 
(VE) provides important information to public health 
authorities, and supports evidence-based policy [1,2]. 
The test-negative study design is now used in many 
locations to provide timely estimates of VE [3,4]. The 
Hong Kong Special Administrative Region is a city with 
a population of 7.3 million, located on the south coast 
of China, and has a subtropical climate. We have been 
monitoring influenza VE in Hong Kong since 2009 [5-7] 
and present here the interim VE estimates in children 
for the 2017/18 winter season.
Influenza activity in Hong Kong 
Influenza circulates for most of the year in Hong Kong, 
with a winter peak in most years. In 2016/17, the winter 
influenza season was dominated by influenza A(H3N2) 
and had a moderate impact. That was followed by a 
very large summer influenza peak in July 2017 domi-
nated by influenza A(H3N2), causing more than 400 
laboratory-confirmed deaths [8]. Influenza activity had 
subsided through the autumn and at the end of 2017, 
influenza activity began to increase again, with influ-
enza B/Yamagata predominating (Figure 1) [9]. In Hong 
Kong, most influenza vaccines are administered in 
October and November each year. Because of the lower 
influenza activity and the contemporaneous adminis-
tration of vaccinations in October and November, we 
focus in this study on the period from 4 December 2017 
through 31 January 2018.
Influenza vaccine effectiveness 
We conducted our study in two large hospitals in Hong 
Kong, Queen Mary Hospital and Princess Margaret 
Hospital [7]. In each hospital we enrolled children 6 
months to 17 years of age who were admitted to the 
general wards of these hospitals with a febrile acute 
respiratory illness, defined as fever of ≥ 38 °C plus any 
respiratory symptom such as cough, runny nose or 
sore throat. Nasopharyngeal aspirates were obtained 
from all patients and tested for influenza A and B 
virus by direct immunofluorescence assay and reverse 
transcription PCR. Influenza vaccination history was 
recorded by research personnel in interviews with par-
ents or legal guardians, using a standardised question-
naire, and compared with electronic medical records 
which contain some but not all influenza vaccinations. 
If parents showed any signs of being uncertain, we 
requested that they check their vaccination record and/
or contact their private doctors if vaccination was done 
in the private sector.
Vaccinated children were those who had received influ-
enza vaccination for the 2017/18 season within the 6 
months before admission in a regimen and dosage 
appropriate for their age and influenza vaccination 
history. Children who needed two doses of influenza 
vaccination but only received one dose, or who had 
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Figure 1
Local influenza activity as reflected by laboratory surveillance data, Hong Kong January 2017–January 2018 (n = 6,636)
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Figure 2
Timeline of recruitment of hospitalised children with acute respiratory illness who tested positive or negative for influenza 
virus by type/subtype, Hong Kong, 4 December 2017–31 January 2018 (n = 1,078)
0
50
100
150
200
Nu
m
be
r o
f a
dm
itt
ed
 c
hi
ld
re
n 
Epidemiological week
Influenza-negative
Influenza B
Influenza A(H3N2)
Influenza A(H1N1)pdm09
49 50 51 52 1 2 3 4 5
2017 2018
3www.eurosurveillance.org
received vaccination within 2 weeks before hospitali-
sation, were categorised as unvaccinated. The 2017/18 
northern hemisphere formulation of trivalent and 
quadrivalent inactivated influenza vaccines were used 
during our study period.
We used conditional logistic regression to estimate 
the effect of influenza vaccination in reducing the risk 
of influenza-associated hospitalisation in children. To 
account for the potential confounding of this causal 
effect by age, we adjusted for age and age squared in 
the statistical model. We matched by epidemiological 
week to account for potential confounding by calendar 
time, since vaccination uptake increases through time 
and the risk of influenza varies over time. Influenza VE 
was estimated as 1 minus the adjusted conditional odds 
ratio (OR), multiplied by 100% [5,6]. Statistical analy-
ses were performed in R version 3.4.0 (R Foundation 
for Statistical Computing, Vienna, Austria).
From 4 December 2017 through 31 January 2018, we 
enrolled 1,078 hospitalised children. Of the 1,078 chil-
dren, 339 (31.4%) tested positive for any influenza 
virus, and 271 of those 339 (79.9%) tested positive for 
influenza B (Figure 2). As local laboratory surveillance 
data indicated, almost all of the influenza B viruses cir-
culating in Hong Kong in that period were B/Yamagata 
lineage viruses (Figure 1).
The characteristics of the 1,078 children are shown in 
the Table.
Among the children who tested negative for influenza, 
103 (13.9%) had been vaccinated, while 22 (6.5%) of 
the children who tested positive for influenza had been 
vaccinated.
We estimated that influenza VE was 65.6% (95% con-
fidence interval (CI): 42.7–79.3) overall, 66.0% (95% 
CI: 3.4–88.0) against influenza A and 65.3% (95% CI: 
39.5–80.1) against influenza B. VE was very similar for 
the quadrivalent vaccine that most vaccinated children 
had received, and we did not have sufficient data to 
estimate VE precisely for children who received the tri-
valent vaccine.
There were 54 children younger than 8 years who had 
not been vaccinated in previous years and therefore 
required two doses of vaccine but had only received 
one dose at the time of admission. In our main anal-
yses, we included these children as unvaccinated 
because one dose is not thought to provide full pro-
tection. In a sensitivity analysis we included these 54 
children as vaccinated instead of unvaccinated, and 
estimated VE to be 58.1% (95% CI: 35.9–72.6) overall 
and 56.7% (31.4–72.7) for influenza B.
Table
Comparison of hospitalised children who tested positive for influenza virus with children who tested negative for influenza, 
Hong Kong, 4 December 2017–31 January 2018 2018 (n = 1,078)
Characteristic
Influenza-positive 
 
(n = 339)
Influenza-negative 
 
(n = 739)
p valuea
n % n %
Age groupb
6 months–2 years 85 25.1 353 47.8
< 0.0013–5 years 123 36.3 226 30.6
6–17 years 131 38.6 160 21.7
Female 158 46.6 323 43.7 0.410
Receipt of influenza vaccinationc
Overall 22 6.5 103 13.9 0.001
By age groupd
6 months–2 years 5 5.9 28 7.9 0.679
3–5 years 9 7.3 45 19.9 0.003
6–17 years 8 6.1 30 18.8 0.003
By type of vaccineb
Quadrivalent inactivated influenza vaccine 14 4.1 83 11.2
0.001
Trivalent inactivated influenza vaccine 2 0.6 6 0.8
Both 0 0 1 0.1
Unknown 6 1.8 13 1.8
a p values estimated by chi-squared tests or Fisher’s exact test whenever appropriate.
b Percentages are per total positive or total negative,
c Receipt of influenza vaccination defined as receipt of a quadrivalent or trivalent inactivated influenza vaccine in an age-appropriate schedule 
within 6 months of hospital admission and at least 2 weeks before admission.
d Percentages are per total positive or negative within the given age group.
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Discussion 
We found that VE against influenza B virus infections 
in children was moderate this winter in Hong Kong, 
consistent with the typical VE of inactivated vac-
cines against influenza B in children [10]. Our esti-
mate was similar to the interim estimate of VE of 55% 
(95% CI: 38–68) against influenza B/Yamagata for the 
2017/18 winter in adults in Canada where the triva-
lent vaccine was used [11], somewhat higher than the 
estimate of 41% (95% CI: 20–56) against influenza B 
in older children and adults in Spain again with the 
trivalent vaccine [12], and somewhat higher than the 
estimate of 42% (95% CI: 25–56) against influenza B in 
the United States [13]. Most vaccinated children in our 
study had received the quadrivalent formulation that 
contained a B/Yamagata component, rather than the 
trivalent formulation that did not. Our findings should 
be reassuring for northern hemisphere locations that 
are currently experiencing epidemics of influenza B/
Yamagata, rather than the influenza A(H3N2) virus for 
which VE was reported to be very low [11]. In our study 
only 20% of influenza patients had influenza A, mostly 
A(H1N1)pdm09, and the estimate of VE against influ-
enza A was less precise.
Influenza vaccination coverage in the children who 
tested negative for influenza is a proxy for vaccina-
tion coverage in the underlying population at risk of 
admission to hospital with influenza in Hong Kong, 
and was around 14% in this study, similar to 15% in 
the 2015/16 season [7], and somewhat higher than the 
average of 9% from 2009/10 to 2013/14 [5]. There is 
still considerable room for increasing the vaccination 
coverage in children. Since 2008, the local govern-
ment has provided a subsidy for influenza vaccination 
administered by private-sector general practitioners to 
children between 6 months and 6 years of age and in 
October 2016, this was extended to children up to 12 
years of age. The current subsidy is HKD 190 (ca EUR 
20), and private general practitioners typically charge 
parents a consultation fee of around HKD 80–120 (EUR 
8–12) in addition to collecting the subsidy. Children in 
low income families and children with underlying medi-
cal conditions are able to receive free vaccination from 
government clinics. One approach to increase vaccina-
tion coverage would be to introduce a school-based 
programme, and this could probably be implemented 
at a much lower cost per dose administered.
A limitation of our study is that we did not have lineage 
typing for the patients with influenza B, although local 
surveillance indicated that B/Yamagata was predomi-
nant. We did not have vaccine effectiveness data on 
adults or outpatients.
Conclusion 
We documented that influenza vaccination was asso-
ciated with good protection against hospitalisation 
for influenza B virus infection in children 6 months to 
17 years of age in Hong Kong in the winter of 2017/18. 
The majority of circulating influenza B viruses were B/
Yamagata lineage.
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